Back
Prelude Therapeutics, Inc. Stock Predictions
AI Powerhouse Raises Price - But Room Remains
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
37
PRLD
Prelude Therapeutics, Inc.
Last Price:
$1.45
Seasonality Move:
-0.12%
7 Day Trial
ALL ACCESS PASS
$
7
Still Time to Get In: RAD Intel at $0.85/Share
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiPrelude Therapeutics, Inc. Stock Forecast
-
Is Prelude Therapeutics, Inc. Stock Undervalued?The current Prelude Therapeutics, Inc. [PRLD] share price is $1.46. The Score for PRLD is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.
-
PRLD is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
Will Prelude Therapeutics, Inc. Stock Go Up Next Year?
Data Unavailable
Prelude Therapeutics, Inc. Stock Rating
Data Unavailable
Prelude Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
preludetx.com
52-Week Data
52-Week High:
4.22
52-Week Low:
0.61
Prediction Charts
Market Cap:
91.8M
Price in USD:
1.46
Volume:
292.8K
Beta:
1.28
Technical Analysis
SMA50:
1.53
SMA100:
1.27
SMA200:
1.05
52-Wk Change:
55.92%
Stock Predictions
-
Is Prelude Therapeutics, Inc. stock public?Yes, Prelude Therapeutics, Inc. is a publicly traded company.
-
What is the Prelude Therapeutics, Inc. stock quote today?The Prelude Therapeutics, Inc. stock price is 1.46 USD today.
-
How to buy Prelude Therapeutics, Inc. stock online?You can buy Prelude Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-17 | 1.52 | 1.65 | 1.69 | 1.46 |
| Nov-18 | 1.63 | 1.68 | 1.73 | 1.55 |
| Nov-19 | 1.65 | 1.67 | 1.70 | 1.61 |
| Nov-20 | 1.65 | 1.60 | 1.68 | 1.50 |
| Nov-21 | 1.61 | 1.67 | 1.69 | 1.52 |
| Nov-24 | 1.66 | 1.40 | 1.66 | 1.40 |
| Nov-25 | 1.42 | 1.59 | 1.60 | 1.32 |
| Nov-26 | 1.59 | 1.67 | 1.68 | 1.53 |
| Nov-28 | 1.66 | 1.68 | 1.70 | 1.60 |
| Dec-1 | 1.67 | 1.55 | 1.67 | 1.51 |
| Dec-2 | 1.55 | 1.35 | 1.55 | 1.34 |
| Dec-3 | 1.33 | 1.38 | 1.40 | 1.30 |
| Dec-4 | 1.34 | 1.54 | 1.55 | 1.34 |
| Dec-5 | 1.56 | 1.46 | 1.56 | 1.43 |
Prelude Therapeutics, Inc. Earnings
Data Unavailable
Prelude Therapeutics, Inc. Forecast Revenue Growth
Data Unavailable
-
Analysts estimate an earnings increase this quarter of $0.07 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.50 per share, and an increase next year of $0.13 per share.
* Prelude Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.